

# Juliane Gust

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/324956/publications.pdf>

Version: 2024-02-01

28  
papers

3,355  
citations

687363

13  
h-index

713466

21  
g-index

29  
all docs

29  
docs citations

29  
times ranked

4098  
citing authors

#	ARTICLE	IF	CITATIONS
1	Endothelial Activation and Bloodâ€ Brain Barrier Disruption in Neurotoxicity after Adoptive Immunotherapy with CD19 CAR-T Cells. <i>Cancer Discovery</i> , 2017, 7, 1404-1419.	9.4	945
2	Kinetics and biomarkers of severe cytokine release syndrome after CD19 chimeric antigen receptorâ€ modified T-cell therapy. <i>Blood</i> , 2017, 130, 2295-2306.	1.4	774
3	Transplantation of Human Embryonic Stem Cell-Derived Photoreceptors Restores Some Visual Function in Crx-Deficient Mice. <i>Cell Stem Cell</i> , 2009, 4, 73-79.	11.1	585
4	Preemptive mitigation of CD19 CAR T-cell cytokine release syndrome without attenuation of antileukemic efficacy. <i>Blood</i> , 2019, 134, 2149-2158.	1.4	194
5	Neurotoxicity Associated with CD19-Targeted CAR-T Cell Therapies. <i>CNS Drugs</i> , 2018, 32, 1091-1101.	5.9	175
6	Locoregional infusion of HER2-specific CAR T cells in children and young adults with recurrent or refractory CNS tumors: an interim analysis. <i>Nature Medicine</i> , 2021, 27, 1544-1552.	30.7	138
7	Glial injury in neurotoxicity after pediatric CD19â€ directed chimeric antigen receptor T cell therapy. <i>Annals of Neurology</i> , 2019, 86, 42-54.	5.3	124
8	Cytokines in CAR T Cellâ€ Associated Neurotoxicity. <i>Frontiers in Immunology</i> , 2020, 11, 577027.	4.8	110
9	Adult Donor Rod Photoreceptors Integrate into the Mature Mouse Retina. , 2011, 52, 5266.		88
10	EGFR806-CAR T cells selectively target a tumor-restricted EGFR epitope in glioblastoma. <i>Oncotarget</i> , 2019, 10, 7080-7095.	1.8	52
11	Decreased Rates of Severe CRS Seen with Early Intervention Strategies for CD19 CAR-T Cell Toxicity Management. <i>Blood</i> , 2016, 128, 586-586.	1.4	45
12	Beyond the storm â€ subacute toxicities and late effects in children receiving CAR T cells. <i>Nature Reviews Clinical Oncology</i> , 2021, 18, 363-378.	27.6	37
13	EEG Correlates of Delirium in Children and Young Adults With CD19-Directed CAR T Cell Treatment-Related Neurotoxicity. <i>Journal of Clinical Neurophysiology</i> , 2021, 38, 135-142.	1.7	15
14	Cytokine release syndrome (CRS) and neurotoxicity (NT) after CD19-specific chimeric antigen receptor- (CAR-) modified T cells.. <i>Journal of Clinical Oncology</i> , 2017, 35, 3020-3020.	1.6	14
15	Blueprint for the discovery of biomarkers of toxicity and efficacy for CAR T cells and T-cell engagers. <i>Blood Advances</i> , 2021, 5, 2519-2522.	5.2	10
16	Chimeric Antigen Receptor T-Cell Neurotoxicity Neuroimaging: More Than Meets the Eye. <i>American Journal of Neuroradiology</i> , 2019, 40, E50-E51.	2.4	9
17	Provider Practices of Phenobarbital Discontinuation in Neonatal Seizures. <i>Journal of Child Neurology</i> , 2018, 33, 153-157.	1.4	8
18	Brain capillary obstruction during neurotoxicity in a mouse model of anti-CD19 chimeric antigen receptor T-cell therapy. <i>Brain Communications</i> , 2022, 4, fcab309.	3.3	8

#	ARTICLE	IF	CITATIONS
19	Neurotoxicities After CAR T-Cell Immunotherapy. , 2020, , 83-105.		7
20	Immunotherapy Associated Neurotoxicity in Pediatric Oncology. Frontiers in Oncology, 2022, 12, 836452.	2.8	5
21	Antibody-based in vivo leukocyte label for two-photon brain imaging in mice. Neurophotonics, 2022, 9, .	3.3	5
22	STRIVE-01: Phase I study of EGFR806 CAR T-cell immunotherapy for recurrent/refractory solid tumors in children and young adults.. Journal of Clinical Oncology, 2022, 40, 2541-2541.	1.6	5
23	Neuro-Oncology Training for the Child Neurology Resident. Journal of Child Neurology, 2021, 36, 79-82.	1.4	1
24	Endothelial Activation and Blood-Brain Barrier Disruption in Neurotoxicity after CD19 CAR-T Cell Immunotherapy. Blood, 2017, 130, 805-805.	1.4	0
25	IMMU-11. BRAINCHILD PIPELINE: LOCOREGIONAL IMMUNOTHERAPY WITH CHIMERIC ANTIGEN RECEPTOR (CAR) T-CELLS FOR RECURRENT/REFRACTORY CENTRAL NERVOUS SYSTEM TUMORS. Neuro-Oncology, 2018, 20, i100-i101.	1.2	0
26	Pediatric ependymoma: New perspectives on older trials. Neuro-Oncology, 2022, , .	1.2	0
27	IMMU-09. Interim analysis from BrainChild-03: Seattle Childrens™s Locoregional B7-H3 CAR T Cell Trial for Children with Recurrent Central Nervous System Tumors and DIPG. Neuro-Oncology, 2022, 24, i83-i83.	1.2	0
28	LTBK-03. Targeted mass spectrometry of serial CSF and serum specimens from children with diffuse intrinsic pontine glioma treated with intracranial B7-H3 CAR T cells. Neuro-Oncology, 2022, 24, i191-i191.	1.2	0